JP2017503830A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503830A5
JP2017503830A5 JP2016548033A JP2016548033A JP2017503830A5 JP 2017503830 A5 JP2017503830 A5 JP 2017503830A5 JP 2016548033 A JP2016548033 A JP 2016548033A JP 2016548033 A JP2016548033 A JP 2016548033A JP 2017503830 A5 JP2017503830 A5 JP 2017503830A5
Authority
JP
Japan
Prior art keywords
pyrazolo
pyrimidin
dimethyl
amine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016548033A
Other languages
English (en)
Japanese (ja)
Other versions
JP6509238B2 (ja
JP2017503830A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/051177 external-priority patent/WO2015110491A2/en
Publication of JP2017503830A publication Critical patent/JP2017503830A/ja
Publication of JP2017503830A5 publication Critical patent/JP2017503830A5/ja
Application granted granted Critical
Publication of JP6509238B2 publication Critical patent/JP6509238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016548033A 2014-01-22 2015-01-21 治療に有用なピラゾロ[1,5−a]ピリミジン−7−アミン誘導体 Active JP6509238B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14152202 2014-01-22
EP14152202.9 2014-01-22
PCT/EP2015/051177 WO2015110491A2 (en) 2014-01-22 2015-01-21 Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy

Publications (3)

Publication Number Publication Date
JP2017503830A JP2017503830A (ja) 2017-02-02
JP2017503830A5 true JP2017503830A5 (https=) 2018-02-22
JP6509238B2 JP6509238B2 (ja) 2019-05-08

Family

ID=49989585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016548033A Active JP6509238B2 (ja) 2014-01-22 2015-01-21 治療に有用なピラゾロ[1,5−a]ピリミジン−7−アミン誘導体

Country Status (11)

Country Link
US (1) US9963455B2 (https=)
EP (1) EP3096762B1 (https=)
JP (1) JP6509238B2 (https=)
CN (1) CN106061975B (https=)
AU (1) AU2015208205B2 (https=)
BR (1) BR112016016798B1 (https=)
CA (1) CA2935658C (https=)
ES (1) ES2954126T3 (https=)
RU (1) RU2689788C2 (https=)
WO (1) WO2015110491A2 (https=)
ZA (1) ZA201605666B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3606926T3 (da) 2017-04-05 2021-07-05 Curovir Ab Heteroaromatiske forbindelser anvendelige i terapi
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
CN108727386A (zh) * 2018-07-16 2018-11-02 广州医科大学 一种吡唑并嘧啶类化合物及其制备方法和用途
SG11202012616RA (en) 2018-08-21 2021-02-25 Kyorin Pharmaceutical Co Ltd Bicyclic heteroaromatic ring derivative
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
CA3115128A1 (en) * 2018-10-10 2020-04-16 Curovir Ab 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP4028131B1 (en) 2019-08-20 2023-11-22 Curovir Ab Heteroaromatic compounds useful in therapy
EP4676485A1 (en) 2023-03-09 2026-01-14 Curovir Ab Compound and formulation for systemic therapy by oral transmucosal administration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585462B2 (ja) * 1989-10-25 1997-02-26 株式会社大塚製薬工場 ピラゾロ[1,5―a]ピリミジン誘導体
KR100191774B1 (ko) * 1991-04-22 1999-06-15 오스카 아끼히꼬 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
JP2003510325A (ja) * 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ[1,5−a]−1,5−ピリミジン及びピラゾロ[1,5−a]−1,3,5−トリアジン
JP2005529919A (ja) * 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
MY137843A (en) * 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
MX2012009866A (es) * 2010-02-26 2012-09-12 Mitsubishi Tanabe Pharma Corp Compuestos pirazolopirimidina y su uso como inhibidores de fosfodiesterasa 10.
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase

Similar Documents

Publication Publication Date Title
JP2017503830A5 (https=)
RU2016134130A (ru) ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ
JP2018522861A5 (https=)
RU2018102449A (ru) Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии
AU2021246118B2 (en) Methods of treating coronavirus
JP2021503458A5 (https=)
JP2007504251A5 (https=)
JP2013209405A5 (https=)
JP2020512337A5 (https=)
JP2019501879A5 (https=)
JP2017522273A5 (https=)
JP2019505529A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2020516599A5 (https=)
RU2011117927A (ru) Карбаматное соединение или его соль
RU2015141360A (ru) Ингибиторы тирозинкиназы брутона
JP2015521156A5 (https=)
JP2006512366A5 (https=)
RU2018123714A (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
JP2015522592A5 (https=)
RU2006138606A (ru) Ингибиторы киназы
RU2015136817A (ru) N-гетероарилзамещенные производные анилина в качестве антивирусных препаратов против вируса гепатита с
RU2007122450A (ru) Применение агониста рецептора 5-нт6 для лечения и профилактики нейродегенеративных заболеваний
FI3941466T3 (fi) Vafidemstat epävakaan persoonallisuushäiriön ei-aggressiivisen oireiden hoitoon
HRP20251471T1 (hr) Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat